Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
T Inoue, Y Yamamoto, K Sato, Y Okemoto-Nakamura… - Iscience, 2024 - cell.com
A current challenge is the emergence of SARS-CoV-2 variants, such as BQ. 1.1 and XBB.
1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness …
1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness …
Novel Omicron Variants Enhance Anchored Recognition of TMEM106B: A New Pathway for SARS-CoV-2 Cellular Invasion
X Zhao, F Gao - The Journal of Physical Chemistry Letters, 2024 - ACS Publications
The recent discovery that TMEM106B serves as a receptor mediating ACE2-independent
SARS-CoV-2 entry into cells deserves attention, especially in the background of the frequent …
SARS-CoV-2 entry into cells deserves attention, especially in the background of the frequent …
Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain
I Anzai, J Fujita, C Ono, Y Kosaka… - Microbiology …, 2024 - Am Soc Microbiol
Although the global crisis caused by the coronavirus disease 2019 (COVID-19) pandemic is
over, the global epidemic of the disease continues. Severe acute respiratory syndrome …
over, the global epidemic of the disease continues. Severe acute respiratory syndrome …
[PDF][PDF] Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents
M Takeshita, H Fukuyama, K Kamada, T Matsumoto… - Iscience, 2023 - cell.com
Several antibody therapeutics have been developed against SARS-CoV-2; however, they
have attenuated neutralizing ability against variants. In this study, we generated multiple …
have attenuated neutralizing ability against variants. In this study, we generated multiple …
Glycyrrhiza glabra L. Extracts and Other Therapeutics against SARS-CoV-2 in Central Eurasia: Available but Overlooked
MZ Zhurinov, AF Miftakhova, V Keyer, ZT Shulgau… - Molecules, 2023 - mdpi.com
In Central Eurasia, the availability of drugs that are inhibitors of the SARS-CoV-2 virus and
have proven clinical efficacy is still limited. The aim of this study was to evaluate the activity …
have proven clinical efficacy is still limited. The aim of this study was to evaluate the activity …
[HTML][HTML] SARS-CoV-2 induces inflammation and intracranial infection through the olfactory epithelium-olfactory bulb pathway in non-human primates
S Shimizu, M Nakayama, CT Nguyen, H Ishigaki… - Journal of …, 2024 - Elsevier
We examined the histopathological changes in the olfactory mucosa of cynomolgus and
rhesus macaque models of SARS-CoV-2 infection. SARS-CoV-2 infection induced severe …
rhesus macaque models of SARS-CoV-2 infection. SARS-CoV-2 infection induced severe …
Diminished neutralizing activity against the XBB1. 5 strain in 55.9% of individuals post 6 months COVID-19 mRNA booster vaccination: insights from a pseudovirus …
T Zhao, Y Tani, C Makino-Okamura, M Takita… - Frontiers in …, 2024 - frontiersin.org
This study investigates the neutralizing activity against the XBB1. 5 variant and the ancestral
strain in a population post-bivalent vaccination using a pseudo virus assay validated with …
strain in a population post-bivalent vaccination using a pseudo virus assay validated with …
[HTML][HTML] Boosted production of antibodies that neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following messenger RNA vaccination-a case …
E Ravlo, A Ianevski, E Starheim, W Wang, P Ji… - International Journal of …, 2023 - Elsevier
Vaccinated convalescents do not develop severe COVID-19 after infection with new SARS-
CoV-2 variants. We questioned how messenger RNA (mRNA) vaccination of convalescents …
CoV-2 variants. We questioned how messenger RNA (mRNA) vaccination of convalescents …